Small Cap📈 NASDAQ: CTMX
CytomX Therapeutics, Inc. (NASDAQ: CTMX)
Published 28 November 2024US Equity Report
CytomX Therapeutics, Inc.
NASDAQ:
CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Franc
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
US Equity Report
A$5000.00
Already a subscriber?
Sign in to read this report.
Required subscription
US Equity Report
Expand beyond the ASX with expert research on carefully selected U.S. stocks, covering market leaders, emerging opportunities, and global investment trends.
- ✓ U.S. Stock Research & Analysis
- ✓ Delivered every Friday
- ✓ Company & Industry Analysis
- ✓ Full Historical Report Access
A$5000.00/ 12 months
Risk:Medium
Subscribe Now →
